Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923011 · ClinicalTrials.gov registry record · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
A Phase 3 study of Osteoid Osteoma, sponsored by Matthew Bucknor.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT02923011: Recruiting Phase 3 study of Osteoid Osteoma, sponsored by Matthew Bucknor.
NCT02923011 is a Phase 3 study of Osteoid Osteoma that is actively recruiting participants, run by Matthew Bucknor. The registered enrollment target is 56 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923011, a Phase 3 study of Osteoid Osteoma, is actively recruiting participants, sponsored by Matthew Bucknor.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events. The data from the current study would provide clinicians important information in deciding between treatment options for ablation of osteoid osteomas.
Primary Outcome
1 month after treatment, worst VAS score over the last 24 hours will be assessed
Conditions Studied
Interventions
- DEVICE MRgFUS
- DEVICE CTgRFA
Study Locations (3)
California
- Stanford Medical Center - Palo Alto
- UCSF Imaging Center - San Francisco
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
What NCT02923011 shows while recruiting
NCT02923011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Osteoid Osteoma appearing as the primary indexed condition, and to 2 interventions - of which MRgFUS is the first listed.
NCT02923011 reports a single indexed study location in California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02923011 about?
NCT02923011 is a clinical study titled "Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas". Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of ...
What is the current status of trial NCT02923011?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2017-03-28. Estimated completion is 2025-06-30.
What conditions does trial NCT02923011 study?
This clinical trial studies the following conditions: Osteoid Osteoma.
What interventions are being tested in trial NCT02923011?
The interventions under investigation include: MRgFUS (DEVICE), CTgRFA (DEVICE).
Who is sponsoring clinical trial NCT02923011?
This trial is sponsored by Matthew Bucknor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02923011 being conducted?
This trial has 3 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoid Osteoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02923011's enrollment target sits among peer trials
56 1828th of 2000 higher than 167 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
- NCT03520647 · 56 participants · Phase 2
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI